Literature DB >> 28770314

Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma.

Song Gao1,2, Seth Stein1, Elena N Petre1, Waleed Shady1, Jeremy C Durack1, Carole Ridge1,3, Prasad Adusumilli4, Natasha Rekhtman5, Stephen B Solomon1, Etay Ziv6.   

Abstract

BACKGROUND: To investigate whether histologic subtyping from biopsies can predict local recurrence after thermal ablation for lung adenocarcinoma.
METHODS: Patients treated with CT-guided thermal ablation for lung adenocarcinoma that had pre-ablation needle biopsy with analysis of histologic components were identified. Age, gender, smoking status, treatment indication (primary stage 1 tumor versus salvage), histologic subtype, ground-glass radiographic appearance, tumor size, ablation modality, and ablation margin were evaluated in relation to time to local recurrence (TTLR). Cumulative incidence of recurrence (CIR) was calculated using competing risks analysis and compared across groups using Fine and Grey method with clustering. Multivariate analysis was conducted with stepwise regression.
RESULTS: There were 53 patients with 57 tumors diagnosed as adenocarcinoma on pre-ablation biopsy and with histologic subtype analysis. Of these, 19% (11) had micropapillary components, 14% (8) had solid components, and 26% (15) had micropapillary and/or solid components. In the univariate analysis, solid (subdistribution hazard ratio [SHR] = 4.04, p = 0.0051, 95% confidence interval [CI] = 1.52-10.7), micropapillary (SHR = 3.36, p = 0.01, CI = 1.33-8.47), and micropapillary and/or solid components (SHR = 5.85, p = 0.00038, CI = 2.21-15.5) were significantly correlated with shorter TTLR. On multivariate analysis, the presence of micropapillary and/or solid component (SHR = 11.4, p = 0.00021, CI: 3.14-41.3) was the only independent predictor of TTLR. The 1-, 2-, and 3-year CIR in patients with micropapillary and/or solid components was 33, 49, and 66% compared to 5, 14, and 18% in patients with no micropapillary or solid components on biopsy specimens.
CONCLUSION: Micropapillary and/or solid histologic components identified in pre-ablation biopsy are associated with shorter TTLR after thermal ablation of lung adenocarcinoma.

Entities:  

Keywords:  Histologic subtype; Local recurrence; Lung ablation; Micropapillary and solid

Mesh:

Year:  2017        PMID: 28770314      PMCID: PMC5760368          DOI: 10.1007/s00270-017-1760-8

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  31 in total

1.  Long-term results of radiofrequency ablation treatment of stage I non-small cell lung cancer: a prospective intention-to-treat study.

Authors:  Marcello Carlo Ambrogi; Olivia Fanucchi; Roberto Cioni; Paolo Dini; Annalisa De Liperi; Carla Cappelli; Federico Davini; Carlo Bartolozzi; Alfredo Mussi
Journal:  J Thorac Oncol       Date:  2011-12       Impact factor: 15.609

2.  Image-guided tumor ablation: standardization of terminology and reporting criteria.

Authors:  S Nahum Goldberg; Clement J Grassi; John F Cardella; J William Charboneau; Gerald D Dodd; Damian E Dupuy; Debra A Gervais; Alice R Gillams; Robert A Kane; Fred T Lee; Tito Livraghi; John McGahan; David A Phillips; Hyunchul Rhim; Stuart G Silverman; Luigi Solbiati; Thomas J Vogl; Bradford J Wood; Suresh Vedantham; David Sacks
Journal:  J Vasc Interv Radiol       Date:  2009-07       Impact factor: 3.464

3.  A note on quantifying follow-up in studies of failure time.

Authors:  M Schemper; T L Smith
Journal:  Control Clin Trials       Date:  1996-08

4.  Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial.

Authors:  Damian E Dupuy; Hiran C Fernando; Shauna Hillman; Thomas Ng; Angelina D Tan; Amita Sharma; William S Rilling; Kelvin Hong; Joe B Putnam
Journal:  Cancer       Date:  2015-06-19       Impact factor: 6.860

5.  Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation.

Authors:  Thierry de Baère; Jean Palussière; Anne Aupérin; Antoine Hakime; Mohamed Abdel-Rehim; Michèle Kind; Clarisse Dromain; Alain Ravaud; Nathalie Tebboune; Valérie Boige; David Malka; Clarisse Lafont; Michel Ducreux
Journal:  Radiology       Date:  2006-08       Impact factor: 11.105

6.  Lung Adenocarcinoma: Predictive Value of KRAS Mutation Status in Assessing Local Recurrence in Patients Undergoing Image-guided Ablation.

Authors:  Etay Ziv; Joseph P Erinjeri; Hooman Yarmohammadi; F Edward Boas; Elena N Petre; Song Gao; Waleed Shady; Constantinos T Sofocleous; David R Jones; Charles M Rudin; Stephen B Solomon
Journal:  Radiology       Date:  2016-07-19       Impact factor: 11.105

7.  Micropapillary and solid subtypes of invasive lung adenocarcinoma: clinical predictors of histopathology and outcome.

Authors:  Min Jae Cha; Ho Yun Lee; Kyung Soo Lee; Ji Yun Jeong; Joungho Han; Young Mog Shim; Hye Sun Hwang
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-04       Impact factor: 5.209

8.  Percutaneous computed tomography-guided lung biopsy and pleural dissemination: an assessment by intraoperative pleural lavage cytology.

Authors:  Yoshifumi Sano; Hiroshi Date; Shinichi Toyooka; Takahiro Oto; Masaomi Yamane; Takao Hiraki; Hideo Gobara; Hidefumi Mimura; Susumu Kanazawa
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

9.  Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center.

Authors:  Waleed Shady; Elena N Petre; Mithat Gonen; Joseph P Erinjeri; Karen T Brown; Anne M Covey; William Alago; Jeremy C Durack; Majid Maybody; Lynn A Brody; Robert H Siegelbaum; Michael I D'Angelica; William R Jarnagin; Stephen B Solomon; Nancy E Kemeny; Constantinos T Sofocleous
Journal:  Radiology       Date:  2015-08-12       Impact factor: 11.105

10.  Factors predicting occult lymph node metastasis in completely resected lung adenocarcinoma of 3 cm or smaller.

Authors:  Jung-Jyh Hung; Yi-Chen Yeh; Wen-Juei Jeng; Yu-Chung Wu; Teh-Ying Chou; Wen-Hu Hsu
Journal:  Eur J Cardiothorac Surg       Date:  2016-01-27       Impact factor: 4.191

View more
  7 in total

1.  CT-Guided Core Biopsy for Peripheral Sub-solid Pulmonary Nodules to Predict Predominant Histological and Aggressive Subtypes of Lung Adenocarcinoma.

Authors:  Ping-Chung Tsai; Yi-Chen Yeh; Po-Kuei Hsu; Chun-Ku Chen; Teh-Ying Chou; Yu-Chung Wu
Journal:  Ann Surg Oncol       Date:  2020-05-03       Impact factor: 5.344

Review 2.  Microwave Ablation in Primary Lung Malignancies.

Authors:  Amgad M Moussa; Etay Ziv; Stephen B Solomon; Juan C Camacho
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

3.  Use of Computed Tomography-Guided Percutaneous Biopsy of Invasive Non-Mucinous Lung Adenocarcinoma to Predict the Degree of Histological Differentiation.

Authors:  Dehao Liu; Lichun Chen; Xiaoping Wang; Yikai Lin; Jianwei Gu
Journal:  Clin Med Insights Oncol       Date:  2022-06-07

4.  Computerized tomography-Guided Microwave Ablation of Patients with Stage I Non-small Cell Lung Cancers: A Single-Institution Retrospective Study.

Authors:  Michael Nance; Zain Khazi; Jussuf Kaifi; Diego Avella; Mohammed Alnijoumi; Ryan Davis; Ambarish Bhat
Journal:  J Clin Imaging Sci       Date:  2021-02-09

5.  Volume and Mass Doubling Time of Lung Adenocarcinoma according to WHO Histologic Classification.

Authors:  Jung Hee Hong; Samina Park; Hyungjin Kim; Jin Mo Goo; In Kyu Park; Chang Hyun Kang; Young Tae Kim; Soon Ho Yoon
Journal:  Korean J Radiol       Date:  2020-10-30       Impact factor: 3.500

Review 6.  Radiogenomics in Interventional Oncology.

Authors:  Amgad M Moussa; Etay Ziv
Journal:  Curr Oncol Rep       Date:  2021-01-02       Impact factor: 5.075

7.  A comprehensive study on the oncogenic mutation and molecular pathology in Chinese lung adenocarcinoma patients.

Authors:  Xilin Zhang; Yan Jiang; Huanming Yu; Hui Xia; Xiang Wang
Journal:  World J Surg Oncol       Date:  2020-07-16       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.